Investigators also look to assess linvoseltamab in relapsed/refractory several myeloma as part of the stage 3 LINKER-MM3 trial.-amplified neuroblastomas and ARMS, and in addition present proof that some tumor entities may not answer also to elimusertib as previously envisioned.SoC remedy-associated genomic evolution reveals applicant alterations th